Tricida (TCDA) Set to Announce Earnings on Monday

Tricida (NASDAQ:TCDAGet Rating) is scheduled to be releasing its earnings data after the market closes on Monday, August 8th. Analysts expect Tricida to post earnings of ($0.52) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Tricida (NASDAQ:TCDAGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.13. On average, analysts expect Tricida to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tricida Price Performance

TCDA opened at $10.86 on Friday. The stock has a fifty day simple moving average of $9.74 and a two-hundred day simple moving average of $9.41. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 584.92. The company has a market cap of $601.92 million, a price-to-earnings ratio of -3.76 and a beta of 0.68. Tricida has a 12-month low of $3.80 and a 12-month high of $12.45.

Insiders Place Their Bets

In other news, major shareholder Venrock Healthcare Capital Par acquired 91,506 shares of the firm’s stock in a transaction on Monday, June 6th. The stock was acquired at an average price of $9.35 per share, for a total transaction of $855,581.10. Following the completion of the acquisition, the insider now owns 5,865,160 shares in the company, valued at $54,839,246. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders bought 999,004 shares of company stock worth $9,517,079. 70.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tricida

Several institutional investors and hedge funds have recently modified their holdings of TCDA. Cresset Asset Management LLC bought a new position in shares of Tricida during the first quarter valued at $1,002,000. Jane Street Group LLC increased its holdings in shares of Tricida by 355.3% during the first quarter. Jane Street Group LLC now owns 109,941 shares of the company’s stock valued at $904,000 after acquiring an additional 85,796 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Tricida by 39.1% during the first quarter. Wellington Management Group LLP now owns 219,143 shares of the company’s stock valued at $1,801,000 after acquiring an additional 61,652 shares in the last quarter. Citigroup Inc. increased its holdings in shares of Tricida by 141.3% during the first quarter. Citigroup Inc. now owns 96,581 shares of the company’s stock valued at $794,000 after acquiring an additional 56,559 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in shares of Tricida during the first quarter valued at $291,000. 79.28% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group decreased their price objective on Tricida from $22.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 24th.

Tricida Company Profile

(Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Further Reading

Earnings History for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.